{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:20:26Z","timestamp":1780413626231,"version":"3.54.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08708"],"award-info":[{"award-number":["23K08708"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adipokines secreted by adipocytes have emerged as critical modulators of cancer progression, particularly in obesity-associated malignancies. However, their therapeutic relevance and the tumor types responsive to adipokine pathways remain unclear. To identify adipokine-driven cancers and assess the therapeutic potential of adipokine signaling, we conducted a pan-cancer transcriptome analysis of the expression of various adipokine receptors in 31 tumor types. AdipoR1 was most frequently amplified and overexpressed in breast cancer across molecular subtypes. In the functional analysis, AdipoR1 stimulation using the agonist AdipoRon activated AMPK signaling, suppressed proliferation and migration, and induced apoptosis in both hormone receptor (HR)-positive (MCF7, T47D) and triple-negative (MDA-MB-231, MDA-MB-468) breast cancer cells. Notably, RNA-Seq analysis revealed that AdipoR1 stimulation upregulated ferroptosis-related genes, DDIT3, HMOX1, and IRE1\u03b1, and downregulated proliferation-related genes, estrogen receptor and TROP2, in breast cancer cell lines. Immunoblotting confirmed these changes at the protein level. AdipoR1 activation enhanced the efficacy of chemotherapeutic agents. In vivo, AdipoRon significantly reduced tumor growth and induced necrotic cell death. AdipoR1 activation exerts multimodal antitumor effects by engaging cell death and hormone receptor signaling. These findings establish AdipoR1 as a valuable therapeutic target in breast cancer and support further development of adipokine receptor-targeting therapies.<\/jats:p>","DOI":"10.1038\/s41419-026-08583-7","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:27:22Z","timestamp":1774513642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AdipoR1\u2013AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-2379","authenticated-orcid":false,"given":"Shinya","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"8583_CR1","first-page":"1757","volume":"59","author":"MJ Bissell","year":"1999","unstructured":"Bissell MJ, Weaver VM, Lelievre SA, Wang F, Petersen OW, Schmeichel KL. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 1999;59:1757\u201363s. discussion 1763s\u201364s.","journal-title":"Cancer Res"},{"key":"8583_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2004.06.010","volume":"6","author":"M Allinen","year":"2004","unstructured":"Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17\u201332.","journal-title":"Cancer Cell"},{"key":"8583_CR3","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garcia-Canaveras JC, Gassaway BM, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 2020;183:1848\u201366.","journal-title":"Cell"},{"key":"8583_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1053\/j.gastro.2011.07.048","volume":"141","author":"BR Achyut","year":"2011","unstructured":"Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011;141:1167\u201378.","journal-title":"Gastroenterology"},{"key":"8583_CR5","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107271","volume":"40","author":"TM Parker","year":"2021","unstructured":"Parker TM, Gupta K, Palma AM, Yekelchyk M, Fisher PB, Grossman SR, et al. Cell competition in intratumoral and tumor microenvironment interactions. EMBO J. 2021;40:e107271.","journal-title":"EMBO J"},{"key":"8583_CR6","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau C, Cao J, Gong D, Gregory MT, Caldwell NJ, Yin X, et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat Genet. 2024;56:2466\u201378.","journal-title":"Nat Genet"},{"key":"8583_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"8583_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","volume":"94","author":"D Fukumura","year":"1998","unstructured":"Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94:715\u201325.","journal-title":"Cell"},{"key":"8583_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ccell.2017.08.013","volume":"32","author":"W Bailis","year":"2017","unstructured":"Bailis W, Shyer JA, Chiorazzi M, Flavell RA. No oxygen? No glucose? No problem: fatty acid catabolism enhances effector CD8(+) TILs. Cancer Cell. 2017;32:280\u20131.","journal-title":"Cancer Cell"},{"key":"8583_CR10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ccell.2021.08.008","volume":"39","author":"Y Lan","year":"2021","unstructured":"Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, et al. Simultaneous targeting of TGF-beta\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39:1388\u2013403.e1310.","journal-title":"Cancer Cell"},{"key":"8583_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"8583_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21:95\u2013104.","journal-title":"Lancet Oncol"},{"key":"8583_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592\u2013604.","journal-title":"Lancet"},{"key":"8583_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643\u201354.","journal-title":"Lancet Oncol"},{"key":"8583_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-022-10059-x","volume":"41","author":"A Mukherjee","year":"2022","unstructured":"Mukherjee A, Bilecz AJ, Lengyel E. The adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022;41:575\u201387.","journal-title":"Cancer Metastasis Rev"},{"key":"8583_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biochi.2023.04.008","volume":"212","author":"J Pestel","year":"2023","unstructured":"Pestel J, Blangero F, Watson J, Pirola L, Eljaafari A. Adipokines in obesity and metabolic-related-diseases. Biochimie. 2023;212:48\u201359.","journal-title":"Biochimie"},{"key":"8583_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01474-4","volume":"22","author":"S Sato","year":"2024","unstructured":"Sato S. Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers. Cell Commun Signal. 2024;22:52.","journal-title":"Cell Commun Signal"},{"key":"8583_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41577-024-01103-8","volume":"25","author":"H Tilg","year":"2025","unstructured":"Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025;25:250\u201365.","journal-title":"Nat Rev Immunol"},{"key":"8583_CR19","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1158\/1541-7786.MCR-20-0991","volume":"19","author":"S Dogra","year":"2021","unstructured":"Dogra S, Neelakantan D, Patel MM, Griesel B, Olson A, Woo S. Adipokine Apelin\/APJ pathway promotes peritoneal dissemination of ovarian cancer cells by regulating lipid metabolism. Mol Cancer Res. 2021;19:1534\u201345.","journal-title":"Mol Cancer Res"},{"key":"8583_CR20","first-page":"4774","volume":"15","author":"CL Huang","year":"2023","unstructured":"Huang CL, Achudhan D, Liu PI, Lin YY, Liu SC, Guo JH, et al. Visfatin upregulates VEGF-C expression and lymphangiogenesis in esophageal cancer by activating MEK1\/2-ERK and NF-kappaB signaling. Aging. 2023;15:4774\u201393.","journal-title":"Aging"},{"key":"8583_CR21","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3390\/biomedicines11092585","volume":"11","author":"M Mallardo","year":"2023","unstructured":"Mallardo M, Scalia G, Raia M, Daniele A, Nigro E. The effects of adiponectin on the behavior of B-cell leukemia cells: insights from an in vitro study. Biomedicines. 2023;11:2585.","journal-title":"Biomedicines"},{"key":"8583_CR22","doi-asserted-by":"publisher","first-page":"bqae030","DOI":"10.1210\/endocr\/bqae030","volume":"165","author":"C Li","year":"2024","unstructured":"Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Adiponectin inhibits the progression of obesity-associated papillary thyroid carcinoma through autophagy. Endocrinology. 2024;165:bqae030.","journal-title":"Endocrinology"},{"key":"8583_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69476-3","volume":"14","author":"J Yoshida","year":"2024","unstructured":"Yoshida J, Hayashi T, Munetsuna E, Khaledian B, Sueishi F, Mizuno M, et al. Adipsin-dependent adipocyte maturation induces cancer cell invasion in breast cancer. Sci Rep. 2024;14:18494.","journal-title":"Sci Rep"},{"key":"8583_CR24","first-page":"23","volume":"13","author":"M Musa Sultan","year":"2024","unstructured":"Musa Sultan M, Hussein Abdullah T, Abbas Abdullah M, Al-Darkazali W, Sattar Harbi N. Evaluate the serum of irisin, omentin-1, and oxidative status in males with prostatic cancer. Rep Biochem Mol Biol. 2024;13:23\u201330.","journal-title":"Rep Biochem Mol Biol"},{"key":"8583_CR25","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.3390\/ijms25168970","volume":"25","author":"A Suzuki","year":"2024","unstructured":"Suzuki A, Sato S, Nakaigawa N, Kishida T, Miyagi Y. Combination of blood adiponectin and leptin levels is a predictor of biochemical recurrence in prostate cancer invading the surrounding adipose tissue. Int J Mol Sci. 2024;25:8970.","journal-title":"Int J Mol Sci"},{"key":"8583_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/pros.24825","volume":"85","author":"H Nagasaka","year":"2025","unstructured":"Nagasaka H, Sato S, Suzuki A, Terao H, Nakamura Y, Yoshihara M, et al. Clinicopathological significance of extranodal adipose tissue invasion in metastatic lymph nodes in patients with prostate cancer. Prostate. 2025;85:283\u201393.","journal-title":"Prostate"},{"key":"8583_CR27","doi-asserted-by":"publisher","first-page":"e202500189","DOI":"10.1002\/cbdv.202500189","volume":"22","author":"BA Rivera-Suarez","year":"2025","unstructured":"Rivera-Suarez BA, Garcia Gonzalez VG, Chimal-Vega B, Navarro Padron AC, Galindo-Hernandez O, Vique-Sanchez JL. Potential ligands to resistin against prostate cancer, evaluated by molecular docking and in vitro assays to develop an anticancer drug. Chem Biodivers. 2025;22:e202500189.","journal-title":"Chem Biodivers"},{"key":"8583_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.tem.2004.07.009","volume":"15","author":"KD Niswender","year":"2004","unstructured":"Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab. 2004;15:362\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"8583_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.102949","volume":"33","author":"D Beck","year":"2022","unstructured":"Beck D, de Lange AG, Alnaes D, Maximov II, Pedersen ML, Leinhard OD, et al. Adipose tissue distribution from body MRI is associated with cross-sectional and longitudinal brain age in adults. Neuroimage Clin. 2022;33:102949.","journal-title":"Neuroimage Clin"},{"key":"8583_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.26654","volume":"45","author":"L Okudzhava","year":"2024","unstructured":"Okudzhava L, Schulz S, Fischi-Gomez E, Girard G, Machann J, Koch PJ, et al. White adipose tissue distribution and amount are associated with increased white matter connectivity. Hum Brain Mapp. 2024;45:e26654.","journal-title":"Hum Brain Mapp"},{"key":"8583_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1677\/ERC-09-0043","volume":"16","author":"T Jarde","year":"2009","unstructured":"Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer. 2009;16:1197\u2013210.","journal-title":"Endocr Relat Cancer"},{"key":"8583_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/me.2009-0498","volume":"24","author":"AY Kim","year":"2010","unstructured":"Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24:1441\u201352.","journal-title":"Mol Endocrinol"},{"key":"8583_CR33","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1158\/1535-7163.MCT-11-0545","volume":"10","author":"HS Moon","year":"2011","unstructured":"Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS. Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther. 2011;10:2234\u201343.","journal-title":"Mol Cancer Ther"},{"key":"8583_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11010-017-2980-6","volume":"431","author":"J Wang","year":"2017","unstructured":"Wang J, Cheng Y, Yin X, Wu J, Luo Y, Wu J, et al. Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1. Mol Cell Biochem. 2017;431:103\u201312.","journal-title":"Mol Cell Biochem"},{"key":"8583_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112338","volume":"593","author":"S Yang","year":"2024","unstructured":"Yang S, Sun Y, Guo Y, Zhao Z, Hu F, Cong L. The glycolysis-related AMPK\/ULK signaling pathway mediates the inhibitory effect of adiponectin in prostate cancer cells. Mol Cell Endocrinol. 2024;593:112338.","journal-title":"Mol Cell Endocrinol"},{"key":"8583_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07084-9","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Uncovering the connection between obesity and thyroid cancer: the therapeutic potential of adiponectin receptor agonist in the AdipoR2-ULK axis. Cell Death Dis. 2024;15:708.","journal-title":"Cell Death Dis"},{"key":"8583_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature12656","volume":"503","author":"M Okada-Iwabu","year":"2013","unstructured":"Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503:493\u20139.","journal-title":"Nature"},{"key":"8583_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0851-z","volume":"9","author":"M Akimoto","year":"2018","unstructured":"Akimoto M, Maruyama R, Kawabata Y, Tajima Y, Takenaga K. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1\/ERK-dependent necroptosis. Cell Death Dis. 2018;9:804.","journal-title":"Cell Death Dis"},{"key":"8583_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11010-019-03586-9","volume":"461","author":"AA Ramzan","year":"2019","unstructured":"Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019;461:37\u201346.","journal-title":"Mol Cell Biochem"},{"key":"8583_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82617-2","volume":"11","author":"K Takenaga","year":"2021","unstructured":"Takenaga K, Akimoto M, Koshikawa N, Nagase H. Obesity reduces the anticancer effect of AdipoRon against orthotopic pancreatic cancer in diet-induced obese mice. Sci Rep. 2021;11:2923.","journal-title":"Sci Rep"},{"key":"8583_CR41","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nature08991","volume":"464","author":"M Iwabu","year":"2010","unstructured":"Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK\/SIRT1. Nature. 2010;464:1313\u20139.","journal-title":"Nature"},{"key":"8583_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cmet.2011.01.012","volume":"13","author":"T Kadowaki","year":"2011","unstructured":"Kadowaki T, Yamauchi T. Adiponectin receptor signaling: a new layer to the current model. Cell Metab. 2011;13:123\u20134.","journal-title":"Cell Metab"},{"key":"8583_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cmet.2011.02.010","volume":"13","author":"M Awazawa","year":"2011","unstructured":"Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011;13:401\u201312.","journal-title":"Cell Metab"},{"key":"8583_CR44","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1249\/MSS.0000000000000237","volume":"46","author":"AF Pagano","year":"2014","unstructured":"Pagano AF, Py G, Bernardi H, Candau RB, Sanchez AM. Autophagy and protein turnover signaling in slow-twitch muscle during exercise. Med Sci Sports Exerc. 2014;46:1314\u201325.","journal-title":"Med Sci Sports Exerc"},{"key":"8583_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04572-8","volume":"13","author":"SJ Manley","year":"2022","unstructured":"Manley SJ, Olou AA, Jack JL, Ruckert MT, Walsh RM, Eades AE, et al. Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. Cell Death Dis. 2022;13:114.","journal-title":"Cell Death Dis"},{"key":"8583_CR46","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijms23073754","volume":"23","author":"TY Jin","year":"2022","unstructured":"Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ. BRCA1\/2 serves as a biomarker for poor prognosis in breast carcinoma. Int J Mol Sci. 2022;23:3754.","journal-title":"Int J Mol Sci"},{"key":"8583_CR47","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/his.12809","volume":"68","author":"SH Kim","year":"2016","unstructured":"Kim SH, Park WS, Yun SI, Joo J, Joung JY, Seo HK, et al. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy. Histopathology. 2016;68:673\u20139.","journal-title":"Histopathology"},{"key":"8583_CR48","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.drudis.2016.05.012","volume":"21","author":"T De Marchi","year":"2016","unstructured":"De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21:1181\u20138.","journal-title":"Drug Discov Today"},{"key":"8583_CR49","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-022-06660-x","volume":"194","author":"N Vidula","year":"2022","unstructured":"Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022;194:569\u201375.","journal-title":"Breast Cancer Res Treat"},{"key":"8583_CR50","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s12013-024-01327-4","volume":"82","author":"N Li","year":"2024","unstructured":"Li N, Xu J, Yan X, Liu Q, Zhang M. TROP2 promotes the proliferation of triple-negative breast cancer cells via calcium ion-dependent ER stress signaling pathway. Cell Biochem Biophys. 2024;82:2205\u201316.","journal-title":"Cell Biochem Biophys"},{"key":"8583_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7262479","volume":"2020","author":"L Sapio","year":"2020","unstructured":"Sapio L, Nigro E, Ragone A, Salzillo A, Illiano M, Spina A, et al. AdipoRon affects cell cycle progression and inhibits proliferation in human osteosarcoma cells. J Oncol. 2020;2020:7262479.","journal-title":"J Oncol"},{"key":"8583_CR52","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/jcm9040940","volume":"9","author":"MY Keung","year":"2020","unstructured":"Keung MY, Wu Y, Badar F, Vadgama JV. Response of breast cancer cells to PARP inhibitors is independent of BRCA status. J Clin Med. 2020;9:940.","journal-title":"J Clin Med"},{"key":"8583_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/biom9070282","volume":"9","author":"AM Alshabi","year":"2019","unstructured":"Alshabi AM, Vastrad B, Shaikh IA, Vastrad C. Exploring the molecular mechanism of the drug-treated breast cancer based on gene expression microarray. Biomolecules. 2019;9:282","journal-title":"Biomolecules"},{"key":"8583_CR54","first-page":"555","volume":"33","author":"X Yu","year":"2008","unstructured":"Yu X, Luo Y, Zhou Y, Zhang Q, Wang J, Wei N, et al. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1\/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol. 2008;33:555\u201363.","journal-title":"Int J Oncol"},{"key":"8583_CR55","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.14052","volume":"10","author":"X Liu","year":"2022","unstructured":"Liu X, Liu H, Zeng L, Lv Y. BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K\/AKT signaling pathway. PeerJ. 2022;10:e14052.","journal-title":"PeerJ"},{"key":"8583_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38977","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Deng J, Zhang H, Tong J, Wan C, Liu Y, et al. Effects of BRCA1 overexpression via the NRF2 \/ HO1 \/ NQO1 pathway on oral cancer cells proliferation, migration, and apoptosis. Heliyon. 2024;10:e38977.","journal-title":"Heliyon"},{"key":"8583_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/35044000","volume":"408","author":"R Scully","year":"2000","unstructured":"Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429\u201332.","journal-title":"Nature"},{"key":"8583_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/0008-5472.CAN-06-4497","volume":"68","author":"JW Evans","year":"2008","unstructured":"Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 2008;68:257\u201365.","journal-title":"Cancer Res"},{"key":"8583_CR59","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10549-005-9036-4","volume":"93","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat. 2005;93:S3\u201310.","journal-title":"Breast Cancer Res Treat"},{"key":"8583_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccell.2016.02.017","volume":"29","author":"S Haricharan","year":"2016","unstructured":"Haricharan S, Lei J, Ellis M. Mammary ductal environment is necessary for faithful maintenance of estrogen signaling in ER(+) breast cancer. Cancer Cell. 2016;29:249\u201350.","journal-title":"Cancer Cell"},{"key":"8583_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-27093-y","volume":"12","author":"H Izci","year":"2022","unstructured":"Izci H, Punie K, Waumans L, Laenen A, Wildiers H, Verdoodt F, et al. Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. Sci Rep. 2022;12:22498.","journal-title":"Sci Rep"},{"key":"8583_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","volume":"76","author":"Y Tsume","year":"2015","unstructured":"Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. Eur J Pharm Sci. 2015;76:203\u201312.","journal-title":"Eur J Pharm Sci"},{"key":"8583_CR63","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1124\/jpet.112.191957","volume":"341","author":"CC Wong","year":"2012","unstructured":"Wong CC, Cheng KW, Rigas B. Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther. 2012;341:572\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"8583_CR64","first-page":"4146","volume":"60","author":"JK Jackson","year":"2000","unstructured":"Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 2000;60:4146\u201351.","journal-title":"Cancer Res"},{"key":"8583_CR65","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GT Consortium","year":"2020","unstructured":"Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318\u201330.","journal-title":"Science"},{"key":"8583_CR66","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI30117","volume":"117","author":"EB Rankin","year":"2007","unstructured":"Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068\u201377.","journal-title":"J Clin Invest"},{"key":"8583_CR67","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","volume":"116","author":"PP Kapitsinou","year":"2010","unstructured":"Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116:3039\u201348.","journal-title":"Blood"},{"key":"8583_CR68","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1074\/jbc.M207198200","volume":"278","author":"UB Pajvani","year":"2003","unstructured":"Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30\/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073\u201385.","journal-title":"J Biol Chem"},{"key":"8583_CR69","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1365-2362.2008.02028.x","volume":"38","author":"S Kaser","year":"2008","unstructured":"Kaser S, Tatarczyk T, Stadlmayr A, Ciardi C, Ress C, Tschoner A, et al. Effect of obesity and insulin sensitivity on adiponectin isoform distribution. Eur J Clin Invest. 2008;38:827\u201334.","journal-title":"Eur J Clin Invest"},{"key":"8583_CR70","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2840-13-103","volume":"13","author":"EZ Fisman","year":"2014","unstructured":"Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.","journal-title":"Cardiovasc Diabetol"},{"key":"8583_CR71","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8583_CR72","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"8583_CR73","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83:3861\u20137.","journal-title":"Cancer Res"},{"key":"8583_CR74","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5:100625.","journal-title":"Innovation"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08583-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08583-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:03:23Z","timestamp":1775257403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08583-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8583"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08583-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS received research funding from Nikon Corporation and Takeda Pharmaceutical Company. YM received research funding from Tosoh Corporation and Shin Nippon Biomedical Laboratories, Ltd. TY received research grants and\/or honoraria for lectures from Chugai, Eisai, Novartis Pharma, Taiho, Nippon Kayaku, AstraZeneca, Kyowa Kirin, Pfizer Japan, Eli Lilly, and Daiichi Sankyo. TY received honoraria for lectures from Chugai, Eisai, Novartis Pharma, AstraZeneca, Kyowa Kirin, Pfizer Japan, Eli Lilly, and Daiichi Sankyo. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}